GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-02-15| Partnerships

Replay And MD Anderson Launches Syena To Lead TCR-NK Cell Therapy

by Joy Lin
Share To

Biotech startup Replay is joining forces with The University of Texas MD Anderson Cancer Center to launch Syena, an oncology company that will develop T-cell receptor (TCR) natural killer (NK) cell therapies.

The new venture will build on the technology from MD Anderson and Replay, combining the safety, potency, and scalability of NK cells with the ability of TCRs to target tumor antigens in cancer cells. Syena’s TCR-NK platform is based on the research of Dr. Katy Rezvani, M.D., PhD, Professor of Stem Cell Transplantation & Cellular Therapy at MD Anderson. 

“This first-in-class TCR-NK technology provides an opportunity for Replay to disrupt the existing cell therapy paradigm and positions Syena to become a leader in this space,” said Adrian Woolfson, Executive Chairman, President, and Co-Founder of Replay. 

“While clinical successes in hematological malignancies have demonstrated the transformative potential of engineered cell therapies, these successes have not yet been realized in solid tumors. NK cells offer distinct advantages over T-cells and building on Dr. Rezvani’s research to arm them with TCRs has the potential to significantly impact oncology cell therapy.”

Related article: Will Breakthrough Therapy Lead the Way? An Overview of the Approved Gene and Cell Therapies for 2022

The Potential of TCR-NK Cell Therapies

Using its TCR-NK cell platform licensed from MD Anderson, Syena will first target a selection of cancer neoantigens. The company’s pipeline will include a program for NY-ESO-1 in hematological malignancies and solid tumors, which is expected to begin clinical trials in the second quarter of 2023. 

Unlike CAR-based therapies, which recognize surface proteins, TCR therapies are designed to recognize proteins that are found inside the cell; a TCR allows NK cells to recognize externalized protein fragments presented by the cell’s surface immune proteins. 

Dr. Rezvani was the first investigator to conduct a clinical trial with cord blood-derived CAR-NK cells and has helped advance 11 cell therapies, such as Affimed’s AFM13, into the clinic with the support of MD Anderson. 

“Dr. Rezvani has generated compelling clinical data with CAR-NK cell therapies, and her expertise with engineered NK cells will prove invaluable in guiding our scientific efforts,” said Lachlan MacKinnon, CEO and Co-Founder of Replay. 

Syena will receive licenses to various Replay cell and genome engineering platform technologies. 

Replay itself is a nascent biotech company, having launched last July in a $55 million seed funding round led by investment firms KKR and OMX Ventures. The San Diego, California-based company has made its mission to expand the scope of genomic medicine by writing and delivering big DNA.  

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Industry Giant Google Backs BIODND—A Precise Life Science Platform Leveraging AI for Efficient Industry Decision-Making
2024-10-17
Nucleate Taiwan Bridging Academia and Industry in the Field of Synbio
2024-07-02
ARPA-H Fast-Tracks Biotech Startups: Funding Insights from BIO 2024 Panel
2024-06-12
LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top